Miao J, Ying B, Li R et al.(2018). Characterization of an N-Terminal Non-Core Domain of RAG1 Gene Disrupted Syrian Hamster Model Generated by CRISPR Cas9. Viruses vol. 10, (5)
Marelli G, Howells A, Lemoine NR et al.(2018). Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer. Frontiers in Immunology vol. 9, 866-866.
Wang P, Li X, Wang J et al.(2018). Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat Commun vol. 9, (1)
Li R, Miao J, Fan Z et al.(2018). Production of Genetically Engineered Golden Syrian Hamsters by Pronuclear Injection of the CRISPR/Cas9 Complex. J Vis Exp (131)
Delaunay T, Violland M, Boisgerault N et al.(2017). Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells. Oncoimmunology vol. 7, (3) e1407897-e1407897.
Wang Z, Wang Y, Wang S et al.(2017). CRISPR-Cas9 HDR system enhances AQP1 gene expression. Oncotarget vol. 8, (67) 111683-111696.
Vincent D, Kramberger P, Hudej R et al.(2017). The development of a monolith-based purification process for Orthopoxvirus vaccinia virus Lister strain. J Chromatogr A vol. 1524, 87-100.
Wang P, Li X, Wang J et al.(2017). Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat Commun vol. 8, (1) 1395-1395.
Spurrell E, Gangeswaran R, Wang P et al.(2017). Correction for Spurrell et al., "STAT1 Interaction with E3-14.7K in Monocytes Affects the Efficacy of Oncolytic Adenovirus". J Virol vol. 91, (20)
Howells A, Marelli G, Lemoine NR et al.(2017). Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer. Front Oncol vol. 7, 195-195.
Cui B, Cao X, Zou W et al.(2017). Regulation of immune-related diseases by multiple factors of chromatin, exosomes, microparticles, vaccines, oxidative stress, dormancy, protein quality control, inflammation and microenvironment: a meeting report of 2017 International Workshop of the Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine on Tumor Immunology. Acta Pharmaceutica Sinica B vol. 7, (4) 532-540.
Lu S, Ahmed T, Du P et al.(2017). Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment. Int J Mol Sci vol. 18, (6)
Webb ES, Liu P, BALEEIRO R et al.(2017). Immune checkpoint inhibitors in cancer therapy. Journal of Biomedical Research
Liu S, Ruban L, Wang Y et al.(2017). Establishing elements of a synthetic biology platform for Vaccinia virus production: BioBrick™ design, serum-free virus production and microcarrier-based cultivation of CV-1 cells. Heliyon vol. 3, (2) e00238-e00238.
Li X, Wang P, Li H et al.(2017). The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model. Clin Cancer Res vol. 23, (1) 239-249.
Yuan M, Wang P, Chard LS et al.(2016). A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors. J Vis Exp (116)
Yuan M, Webb E, Lemoine NR et al.(2016). CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses. Viruses vol. 8, (3)
Ibrahim AM, Wang Y-H(2016). Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World J Gastroenterol vol. 22, (2) 748-763.
Ibrahim AM, Wang Y, Lemoine NR(2015). Immune-checkpoint blockade: the springboard for immuno-combination therapy. Gene Ther vol. 22, (11) 849-850.
Chard LS, Lemoine NR, Wang Y(2015). New role of Interleukin-10 in enhancing the antitumor efficacy of oncolytic vaccinia virus for treatment of pancreatic cancer. Oncoimmunology vol. 4, (9)
Browne A, Tookman LA, Ingemarsdotter CK et al.(2015). Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity. Cancer Res vol. 75, (14) 2811-2821.
Hughes J, Wang P, Alusi G et al.(2015). Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus. Gene Ther vol. 22, (6) 476-484.
Yuan M, Zhang W, Wang J et al.(2015). Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system. J Virol vol. 89, (9) 5176-5179.
Ferguson M, Tysome J, Burns E et al. (2015). Targeting Innate Host Immunity Through PI3K Delta for Enhancement of Systemic Delivery of Oncolytic Vaccinia Virus. MOLECULAR THERAPY. vol. 23, S258-S259.
Hughes JP, Alusi G, Wang Y(2015). Viral gene therapy for head and neck cancer. J Laryngol Otol vol. 129, (4) 314-320.
Chard LS, Maniati E, Wang P et al.(2015). A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer. Clin Cancer Res vol. 21, (2) 405-416.
Yuan M, Gao X, Chard LS et al.(2015). A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9. Mol Ther Methods Clin Dev vol. 2,
Al Yaghchi C, Zhang Z, Alusi G et al.(2015). Vaccinia virus, a promising new therapeutic agent for pancreatic cancer. Immunotherapy vol. 7, (12) 1249-1258.
Hughes J, Wang P, Alusi G et al. (2014). Backbone selection for development of tumour-targeted oncolyti Vaccinia virus for cancer treatment. HUMAN GENE THERAPY. vol. 25, A22-A23.
Ahmed J, Yuan M, Li Y et al. (2014). A Novel Tumour Selective Oncolytic Vaccinia Virus Lacking the N1L Gene Enhances the Anti-Tumour Immune Response When Used as an Anticancer Therapeutic. MOLECULAR THERAPY. vol. 22, S248-S249.
Spurrell E, Gangeswaran R, Wang P et al.(2014). STAT1 interaction with E3-14.7K in monocytes affects the efficacy of oncolytic adenovirus. Journal of Virology vol. 88, (4) 2291-2300.
Chard LS, Maniati E, Wang P et al. (2013). A Vaccinia Virus Armed with Interleukin-10 That Dampens Host Immunity to the Vctor but Not to Tumor Is a Promising Therapeutic Agent for Pancreatic Cancer. MOLECULAR THERAPY. vol. 21, S196-S196.
Hughes J, Wang P, Alusi G et al. (2013). Lister Strain Vaccinia Virus Demonstrates Favourable Anti-Tumor Efficacy and Tumor-Selectivity Compared to Western Reserve Strain. MOLECULAR THERAPY. vol. 21, S216-S216.
Cheung W, Nowrouzi A, Coutelle C et al. (2013). The fetal mouse is a model of genotoxicity that can uncover genes involved in liver cancer. HUMAN GENE THERAPY. vol. 24, A15-A16.
Hiley CT, Chard LS, Gangeswaran R et al.(2013). Vascular endothelial growth factor A promotes vaccinia virus entry into host cells via activation of the Akt pathway. J Virol vol. 87, (5) 2781-2790.
Nowrouzi A, Cheung WT, Li T et al.(2013). The Fetal Mouse Is a Sensitive Genotoxicity Model That Exposes Lentiviral-associated Mutagenesis Resulting in Liver Oncogenesis. MOLECULAR THERAPY vol. 21, (2) 324-337.
Tysome JR, Lemoine NR, Wang Y(2013). Update on oncolytic viral therapy - targeting angiogenesis. Onco Targets Ther vol. 6, 1031-1040.
Tysome JR, Li X, Wang S et al.(2012). A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity. Clin Cancer Res vol. 18, (24) 6679-6689.
Hughes J, Alusi G, Wang Y(2012). Gene therapy and nasopharyngeal carcinoma. RHINOLOGY vol. 50, (2) 115-121.
Wang P, Jiang G, Chard L et al. (2012). A Rationally Designed Oncolytic Adenovirus, Ad-TD-IL-12, Cures Pancreatic Cancer in the Immunocompetent Syrian Hamster. MOLECULAR THERAPY. vol. 20, S131-S131.
Yang Y, Li X, Wang Y et al.(2012). CD8+T cell response mediates the therapeutic effects of oncolytic adenovirus in an immunocompetent mouse model. CANCER RESEARCH vol. 72,
YaJun Y, XiaoZhu L, YaoHe W et al.(2012). CD8(+) T cell response mediates the therapeutic effects of oncolytic adenovirus in an immunocompetent mouse model. CHINESE SCIENCE BULLETIN vol. 57, (1) 48-53.
WANG Y(2012). Modification of the Early Gene Enhancer-promoter Improves the Oncolytic Potency of Adenovirus 11. Mol Ther vol. 20, (2) 306-16.
Ferguson MS, Lemoine NR, Wang Y(2012). Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol vol. 2012,
Tysome JR, Wang P, Alusi G et al.(2011). Lister vaccine strain of vaccinia virus armed with the endostatin-angiostatin fusion gene: an oncolytic virus superior to dl1520 (ONYX-015) for human head and neck cancer. Hum Gene Ther vol. 22, (9) 1101-1108.
Jiang G, Cao F, Ren G et al.(2010). PRSS3 promotes tumour growth and metastasis of human pancreatic cancer. Gut vol. 59, (11) 1535-1544.
Hiley CT, Yuan M, Lemoine NR et al.(2010). Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours. Gene Ther vol. 17, (2) 281-287.
Wong HH, Lemoine NR, Wang Y(2010). Oncolytic viruses for cancer therapy: overcoming the obstacles. Viruses vol. 2, (1) 78-106.
Tysome JR, Lemoine NR, Wang YH(2009). Combination of anti-angiogenic therapy and virotherapy: Arming oncolytic viruses with anti-angiogenic genes. CURR OPIN MOL THER vol. 11, (6) 664-669.
Tysome JR, Briat A, Alusi G et al.(2009). Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther vol. 16, (10) 1223-1233.
Wang YH, Gangeswaran R, Zhao XB et al.(2009). CEACAM6 attenuates adenovirus infection by antagonizing viral trafficking in cancer cells. J CLIN INVEST vol. 119, (6) 1604-1615.
Wong HH, Gangeswaran R, Francis J et al. (2009). Adenovirus 11 is an Alternative Oncolytic Virus Targeting Adenovirus 5-Insensitive Cancer and Shows Distinct E1A Gene Transcriptional Activity. MOLECULAR THERAPY. vol. 17, S235-S236.
Tysome JR, Briat A, Hiley C et al. (2009). Systemic Delivery of Lister Strain Vaccinia Virus to Tumors Is Facilitated by the Depletion of Macrophages in Immuno-Competent Mice. MOLECULAR THERAPY. vol. 17, S247-S247.
Tysome JR, Briat A, Alusi G et al.(2009). Lister strain of vaccinia virus armed with endostatin–angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancerVaccine strain of vaccinia virus for cancer therapy. Gene Therapy vol. 16, (10) 1223-1233.
Kirn DH, Wang YH, Liang WC et al.(2008). Enhancing poxvirus oncolytic effects through increased spread and immune evasion. CANCER RES vol. 68, (7) 2071-2075.
Cheong SC, Wang Y, Meng J-H et al.(2008). E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther vol. 15, (1) 40-50.
Kirn DH, Wang YH, Le Boeuf F et al.(2007). Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLOS MED vol. 4, (12) Article e353, 2001-2012.
Thorne SH, Hwang THH, O'Gorman WE et al.(2007). Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J CLIN INVEST vol. 117, (11) 3350-3358.
Lopes RB, Gangeswaran R, McNeish IA et al.(2007). Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int J Cancer vol. 120, (11) 2344-2352.
Themis M, Waddington SN, Schmidt M et al.(2006). Oncogenesis Following Delivery of Lentiviral Vectors to Fetal and Neonatal Mice. MOLECULAR THERAPY vol. 13, S320-S320.
Themis M, Waddington SN, Schmidt M et al.(2006). Corrigendum to "Oncogenesis Following Delivery of a Nonprimate Lentiviral Gene Therapy Vector to Fetal and Neonatal Mice". Mol Ther vol. 13, (4)
Themis M, Waddington SN, Schmidt M et al.(2006). Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice (vol 12, pg 763, 2005). MOL THER vol. 13, (4) 830-830.
Themis M, Waddington SN, Schmidt M et al. (2006). Oncogenesis following delivery of a non-primate lentiviral gene therapy vector to fetal mice. TOXICOLOGY. vol. 219, 233-233.
Lockley M, Fernandez M, Wang Y et al.(2006). Activity of the adenoviral E1A deletion mutant dl922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin. Cancer Res vol. 66, (2) 989-998.
Themis M, Waddington SN, Schmidt M et al.(2005). Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. MOL THER vol. 12, (4) 763-771.
Liu T-C, Wang Y, Hallden G et al.(2005). Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus. Gene Ther vol. 12, (17) 1333-1346.
Tan PH, Beutelspacher SC, Xue S-A et al.(2005). Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood vol. 105, (10) 3824-3832.
Tan PH, Beutelspacher SC, Wang YH et al. (2005). Immunolipoplexes: An efficient, non-viral alternative for transfection of human dendritic cells with potential for clinical vaccination. AMERICAN JOURNAL OF TRANSPLANTATION. vol. 5, 367-367.
Tan PH, Beutelspacher SC, Wang Y-H et al.(2005). Immunolipoplexes: an efficient, nonviral alternative for transfection of human dendritic cells with potential for clinical vaccination. Mol Ther vol. 11, (5) 790-800.
Tan PH, Xue SA, Wang YH et al. (2005). Modulation of human dendritic cell function following viral vectors: implications for gene therapy in vaccination. BRITISH JOURNAL OF SURGERY. vol. 92, 134-134.
Wang Y, Xue S-A, Hallden G et al.(2005). Virus-associated RNA I-deleted adenovirus, a potential oncolytic agent targeting EBV-associated tumors. Cancer Res vol. 65, (4) 1523-1531.
Wang Y, Thorne S, Hannock J et al.(2005). A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses. Clin Cancer Res vol. 11, (1) 351-360.
Missiaglia E, Blaveri E, Terris B et al.(2004). Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int J Cancer vol. 112, (1) 100-112.
Groot-Wassink T, Aboagye EO, Wang Y et al.(2004). Noninvasive imaging of the transcriptional activities of human telomerase promoter fragments in mice. Cancer Res vol. 64, (14) 4906-4911.
Wang Y, Faux SP, Hallden G et al.(2004). Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite. Int J Oncol vol. 25, (1) 173-178.
Liu T-C, Hallden G, Wang Y et al.(2004). An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency. Mol Ther vol. 9, (6) 786-803.
Hallden GK, Meng JH, Hill R et al. (2004). Combination therapy with adenovirus (Ad5) and cytotoxic drugs can act synergistically to induce cell death in carcinoma cell lines in culture. MOLECULAR THERAPY. vol. 9, S113-S113.
Liu TC, Wang YH, Hallden G et al. (2004). Oncolytic adenovirus E1B-19kD deletion and E3B retention results in both enhanced potency and tumor necrosis factor-mediated selectivity. MOLECULAR THERAPY. vol. 9, S109-S109.
Hill RJ, Hallden GK, Wang YH et al. (2004). The gene expression and function of adenoviral E3-genes in murine tumour cell lines. MOLECULAR THERAPY. vol. 9, S374-S375.
Wang YH, Xue SA, Hallden G et al. (2004). VAI deleted adenovirus as an oncolytic agent targeting human EBV-associated tumours. MOLECULAR THERAPY. vol. 9, S230-S230.
Groot-Wassink T, Aboagye EO, Wang Y et al.(2004). Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol Ther vol. 9, (3) 436-442.
Wang Y, Hallden G, Hill R et al.(2003). E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol vol. 21, (11) 1328-1335.
Halldén G, Hill R, Wang Y et al.(2003). Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther vol. 8, (3) 412-424.
Liu TC, Wang YH, Hallden G et al. (2003). Adenoviral E1B-19kD deletion results in enhanced oncolytic effect and reduced toxicity in an immunocompetent murine tumor. MOLECULAR THERAPY. vol. 7, S416-S416.
Wang YH, Francis J, Griffin BE et al. (2003). Cytotoxicity of replication-competent adenovirus to lymphoproliferative disorders correlates with expression of heparan sulfate. MOLECULAR THERAPY. vol. 7, S359-S359.
Liu TC, Hallden G, Anand A et al. (2003). Adenovirus E1B-19kD gene deletion enhances oncolytic virus efficacy and selectivity. CANCER GENE THERAPY. vol. 10, S20-S20.
LEMOINE N, Vassaux G, Groot-Wassink T et al.(2003). Cellular characterisation of the tropism of recombinant adenovirus for the adrenal glands. Eur. J. Clin. Invest. vol. 33, 794-798.